TECHWIRE 30
(CIX: WRAL30)  981.51  up arrow+2.42  (0.25 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NQ: Apple)  517.96  down arrow-3.72  (-0.71 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NY: QUINTILES)  50.67  up arrow+0.12  (0.24 %)  Updated: 06:40 PM EDT, Apr 15 2014
(OP: BASF SE)  106.59  down arrow-1.11  (-1.03 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NQ: BioCryst)  8.33  up arrow+0.08  (0.97 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NQ: BioDelivery)  7.13  down arrow-0.05  (-0.7 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NQ: CEMP)  8.73  down arrow-0.12  (-1.36 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NQ: Cisco Systems)  22.89  up arrow+0.04  (0.18 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NQ: Cornerstone)  9.49    (0 %)  Updated: 08:10 PM EST, Feb 03 2014
(NQ: Cree)  55.51  up arrow+0.59  (1.07 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NQ: DARA)  2.50  down arrow-0.1  (-3.85 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NY: EMC CORPORATION)  26.92  up arrow+0.17  (0.64 %)  Updated: 06:40 PM EDT, Apr 15 2014
(NQ: Extreme Networks)  5.65  up arrow+0.03  (0.53 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NQ: Facebook)  59.09  up arrow+0.2  (0.34 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NY: GLAXOSMITHKLINE)  52.32  up arrow+0.48  (0.93 %)  Updated: 06:40 PM EDT, Apr 15 2014
(NQ: GOOG)  536.44  up arrow+3.92  (0.74 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NY: IBM)  197.02  down arrow-0.75  (-0.38 %)  Updated: 06:40 PM EDT, Apr 15 2014
(NY: LH)  101.56  up arrow+0.81  (0.8 %)  Updated: 06:40 PM EDT, Apr 15 2014
(OP: Lenovo Group)  23.40  down arrow-0.9  (-3.7 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NY: MRK)  56.05  up arrow+0.48  (0.86 %)  Updated: 06:40 PM EDT, Apr 15 2014
(NQ: Microsoft Corp)  39.75  up arrow+0.57  (1.45 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NQ: NetApp)  37.00  up arrow+0.21  (0.56 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NY: NOVARTIS AG)  83.79  down arrow-0.04  (-0.05 %)  Updated: 06:40 PM EDT, Apr 15 2014
(OP: Novozymes A/S)  43.66  up arrow+0.86  (2.01 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NY: PFIZER)  29.89  up arrow+0.02  (0.07 %)  Updated: 06:40 PM EDT, Apr 15 2014
(NQ: Pozen)  8.47  down arrow-0.18  (-2.08 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NY: RED HAT)  50.10  up arrow+0.27  (0.54 %)  Updated: 06:40 PM EDT, Apr 15 2014
(NQ: BBRY)  7.21  up arrow+0.07  (0.98 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NQ: Salix)  98.19  up arrow+0.49  (0.5 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NQ: SQI)  25.03  down arrow-0.11  (-0.44 %)  Updated: 08:10 PM EDT, Apr 15 2014

Posts tagged “Biotech & Life Science”

4:18 p.m. yesterday

Bees get a sweet boost in Bayer CropScience 'Care Center'

Bayer CropScience on Tuesday unveiled the 6,000-square-foot building to promote honey bee health and well-being through public education exhibits for visitors, a conference room and a research lab. The vision is to have students mingle with company scientists and other bee experts to study ways to reverse the decline in the important pollinators' populations.

The new Bee Care Center The new Bee Care Center

6:04 a.m. Monday

Sebelius: Healthcare.gov launch 'terribly flawed'

Obama Health Secretary Resignation The Obama administration's timeline for having ready the new health care law's online sign-up system "was just flat out wrong," outgoing Health and Human Services Secretary Kathleen Sebelius said in an interview that aired Sunday.

5:44 a.m. Monday

Week in review: The 21 latest headlines from WRALTechWire

Week in review A look back at technology, life science and other related news as reported in WRAL Tech Wire last week.

5:27 a.m. Monday

Looking for news: Send your company updates to WRALTechWire

Contribute to WRALTechWire WRALTechWire is continuously expanding its content lineup, and we want you to participate. We are looking for news and analysis about all things tech and life science from people who know their business.

Updated April 10

Premium Lock 'Be Well' doctor joins medical team at PurThread

Renowned physician Dr. Russell Greenfield - a regular contributor to The Dr. Oz Show and an author - has been named the new medical director for PurThread in North Carolina.

The Be Well Doctor The Be Well Doctor

April 9

Chimerix names new CEO after Moch steps down

Chimerix Kenneth Moch has resigned as chief executive of the biopharmaceutical company to "pursue other interests," the company announced on Wednesday while also naming his replacement.

April 8

GSK launches probe into Iraq bribery claims

GSK's HQ in London     Drug giant GlaxoSmithKline said Monday it has launched an investigation into allegations it bribed doctors in Iraq, as the pharmaceuticals giant remains embroiled in a major corruption scandal in China.

April 8

So when will Scynexis go public? Street sites offer different dates

The Durham drug-development company was expected to go public last week, but those plans were delayed. Now, two Wall Street news sites offer different possibilities for the IPO.

Scynexis Scynexis

Updated April 7

Mallinckrodt, which has two plants in Raleigh, acquires drug firm for $5.2B

Drugs  Ireland-based Mallinckrodt is buying Questcor Pharmaceuticals Inc. in a deal valued at about $5.2 billion that will help to diversify its business. Mallinckrodt CEO will lead the merged operation.

April 7

Week in review: The 55 latest headlines from WRALTechWire

Week in review A look back at technology, life science and other related news as reported in WRAL Tech Wire last week.

April 4

Scynexis IPO delay faces uncertain timetable

The Durham drug-development company was expected to go public this week, but those plans seem to have changed.

Scynexis Scynexis

April 3

Premium Lock How do you find a job? Network, say recruiting experts

Jobs At a recent jobs and recruiting event put on by the NCBiotech Jobs Network, three corporate recruits stressed one important fact for job seekers: Networking is crucial.

April 3

Premium Lock Scynexis likely to become latest Triangle IPO today - but at sharply lower price

The Durham-based drug firm has finalized plans to begin selling shares between $7 and $8 on Thursday on the Nasdaq under the symbol SCYX. The nasdaq says the IPO is expected to begin at some point today after trading opens. However, the share price is well under an earlier targeted range of between $12 and $14 a share. Scynexis also is doubling the number of shares available.

The Scynexis pipeline The Scynexis pipeline

April 3

Premium Lock Med device firm TransEnterix launches $50M stock offering

The RTP-based medical device firm is moving ahead with plans to raise as much as $100 million through a stock offering. A new filing with the SEC shows that shares will become available today. The capital raising effort is the latest in a series of moves by TransEnterix to grow the company and to raise funding for a new robotic surgery device.

TransEnterix TransEnterix

April 2

Premium Lock Scynexis sharply lowers target price for stock in IPO, doubles number of shares

The Durham-based drug firm has finalized plans to begin selling shares between $7 and $8 on Thursday on the Nasdaq under the symbol SCYX. That's well under an earlier targeted range of between $12 and $14 a share. Scynexis also is doubling the number of shares available.

Scynexis Scynexis

April 2

Premium Lock Drug giant Baxter acquires Chapel Hill firm for $70M

Heart research Baxter International is acquiring Chapel Hill-based Chatham Therapeutics to gain control of gene-based therapy technology focused on hemophilia. The deal includes a $70 million upfront payment. Additional payments could be made based on development, regulatory and commercial milestones.

Updated April 2

Premium Lock Startup Keona Health dials in to $2.5M in new capital

From humble beginnings as a startup at the LaunchBox Digital accelerator in 2011 to receiving an NC IDEA grant to winning a six-figure prize in an Allscripts challenge to $2.5 million in venture capital: That's the quick growth story of Chapel Hill's Keona Health, which aims to change how medical practices deal initially with patients.

Keona Health helps nurses "triage" patient calls Keona Health helps nurses "triage" patient calls

Updated April 2

Premium Lock Todd Pope's latest moves mean reverse stock split, new exchange for TransEnterix

After disclosing its latest update to the FDA about the company's robotic surgery technology, RTP-based TransEnterix moves to raise its profile. It also has plans to raise as much as $100 million in capital.

TransEnterix CEO Todd Pope TransEnterix CEO Todd Pope

April 1

Exec rejoins NC Biotech Center's western office

N.C. Biotech Center Jonathon Lawrie has re-joined the North Carolina Biotechnology Center as executive director of the Western Office in Asheville, as a result of Dale Carroll's decision to leave the post to become CEO of a newly formed regional economic development organization.

Updated April 1

Premium Lock Scynexis looks to go public Thursday at $55M

The Durham-based drug firm has finalized plans to begin selling shares between $12 and $14 on Thursday on the Nasdaq under the symbol SCYX. The company does not yet have a drug on the market and lost some $30 million in 2013.

Scynexis Scynexis

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Dr. Mike Walden
Tech economy
Vivek Wadhwa
Commentary
Frank Vinluan
Life science
Scroll